158 related articles for article (PubMed ID: 22899340)
1. Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression.
Low HZ; Hilbrans D; Schmidt-Wolf IG; Illges H
Int J Hematol; 2012 Sep; 96(3):350-6. PubMed ID: 22899340
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.
Gagro A; Dasić G; Sabioncello A; Rabatić S; Reckzeh B; Havemann K; Kardum I; Jacksić B; Vitale B
Leuk Lymphoma; 1997 Apr; 25(3-4):301-11. PubMed ID: 9168440
[TBL] [Abstract][Full Text] [Related]
3. Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia.
Lopez-Matas M; Rodriguez-Justo M; Morilla R; Catovsky D; Matutes E
Haematologica; 2000 Nov; 85(11):1140-5. PubMed ID: 11064465
[TBL] [Abstract][Full Text] [Related]
4. A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.
Nichols EM; Jones R; Watson R; Pepper CJ; Fegan C; Marchbank KJ
Oncotarget; 2015 Oct; 6(32):32669-80. PubMed ID: 26452134
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B cells.
Frémeaux-Bacchi V; Fischer E; Lecoanet-Henchoz S; Mani JC; Bonnefoy JY; Kazatchkine MD
Int Immunol; 1998 Oct; 10(10):1459-66. PubMed ID: 9796912
[TBL] [Abstract][Full Text] [Related]
6. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM
Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605
[TBL] [Abstract][Full Text] [Related]
7. B cell activation leads to shedding of complement receptor type II (CR2/CD21).
Masilamani M; Kassahn D; Mikkat S; Glocker MO; Illges H
Eur J Immunol; 2003 Sep; 33(9):2391-7. PubMed ID: 12938215
[TBL] [Abstract][Full Text] [Related]
8. Ectodomain shedding and generation of two carboxy-terminal fragments of human complement receptor 2/CD21.
Hoefer MM; Illges H
Mol Immunol; 2009 Aug; 46(13):2630-9. PubMed ID: 19524299
[TBL] [Abstract][Full Text] [Related]
9. Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis.
Masilamani M; von Kempis J; Illges H
Rheumatology (Oxford); 2004 Feb; 43(2):186-90. PubMed ID: 12867574
[TBL] [Abstract][Full Text] [Related]
10. Pathways controlling the expression of surface CD21 (CR2) and CD23 (Fc(epsilon)IIR) proteins in human malignant B cells.
Shubinsky G; Schlesinger M; Polliack A; Rabinowitz R
Leuk Lymphoma; 1997 May; 25(5-6):521-30. PubMed ID: 9250823
[TBL] [Abstract][Full Text] [Related]
11. Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease.
Masilamani M; Rajasekaran N; Singh A; Low HZ; Albus K; Anders S; Behne F; Eiermann P; König K; Mindnich C; Ribarska T; Illges H
Rheumatol Int; 2008 Sep; 28(11):1137-41. PubMed ID: 18500464
[TBL] [Abstract][Full Text] [Related]
12. Detection of sCD21 in Human Blood Using ELISA is Influenced by Ethylenediaminetetraacetic Acid (EDTA) Containing Blood Collection Tubes.
Linke K; Illges H
Clin Lab; 2015; 61(11):1803-8. PubMed ID: 26732009
[TBL] [Abstract][Full Text] [Related]
13. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
Frémeaux-Bacchi V; Bernard I; Maillet F; Mani JC; Fontaine M; Bonnefoy JY; Kazatchkine MD; Fischer E
Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
[TBL] [Abstract][Full Text] [Related]
14. Soluble CD21 in sera and synovial fluid of arthritic patients.
Grottenthaler T; von Kempis J; Goldacker S; Illges H
Rheumatol Int; 2006 Jan; 26(3):240-3. PubMed ID: 15770483
[TBL] [Abstract][Full Text] [Related]
15. The increased expression of CD21 on AchR specified B cells in patients with myasthenia gravis.
Yin W; Allman W; Ouyang S; Li Y; Li J; Christadoss P; Yang H
J Neuroimmunol; 2013 Mar; 256(1-2):49-54. PubMed ID: 23266128
[TBL] [Abstract][Full Text] [Related]
16. Purification and characterization of soluble CD21 from human plasma by affinity chromatography and density gradient centrifugation.
Masilamani M; Apell HJ; Illges H
J Immunol Methods; 2002 Dec; 270(1):11-8. PubMed ID: 12379334
[TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukemia/small lymphocytic lymphoma: another neoplasm related to the B-cell follicle?
Tandon B; Swerdlow SH; Hasserjian RP; Surti U; Gibson SE
Leuk Lymphoma; 2015; 56(12):3378-86. PubMed ID: 25860247
[TBL] [Abstract][Full Text] [Related]
18. Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein.
Braun M; Melchers I; Peter HH; Illges H
Int Immunol; 1998 Aug; 10(8):1197-202. PubMed ID: 9723706
[TBL] [Abstract][Full Text] [Related]
19. The autocrine motility factor receptor is overexpressed on the surface of B cells in Binet C chronic lymphocytic leukemia.
Grund S; Olsson B; Jernås M; Jacobsson S; Swolin B; Nabi IR; Carlsson L; Wadenvik H
Med Oncol; 2011 Dec; 28(4):1542-8. PubMed ID: 20574759
[TBL] [Abstract][Full Text] [Related]
20. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.
Huang PY; Best OG; Almazi JG; Belov L; Davis ZA; Majid A; Dyer MJ; Pascovici D; Mulligan SP; Christopherson RI
Leuk Lymphoma; 2014 Sep; 55(9):2085-92. PubMed ID: 24289109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
